A single-tube NGS assay for simultaneous detection of DNA and RNA biomarkers as a comprehensive solution for clinical management and guiding therapeutic intervention of Ph-like ALL patients
Literature
Read More
Case Study: How Pharma Uses NeoGenomics Real-World Oncology Data to Accelerate Biomarker Adoption and Commercial Launch
Blog
Read More
NeoGenomics Provides Update on MolDX Submission for CRC and RaDaR(TM) Commercial Launch
Press Release
Read More
NeoGenomics announces speaker program, ‘Minimal Residual Disease in Colorectal Cancer’
Blog
Read More
NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
Press Release
Read More